Milton Keynes University Hospital (MKUH) is proud to announce that Consultant Urologist Mr. Sonpreet Rai and his team have become the first hospital in the region to treat patients using Optilume.
This innovative, minimally invasive treatment offers new hope to patients suffering from urethral strictures, a condition that can cause difficulty with urination and significant discomfort.
Mr. Rai and the urology team are committed to providing cutting-edge treatments to improve patient outcomes and enhance their quality of life. The introduction of Optilume represents a significant advancement in managing this challenging condition, where traditional treatments have posed limitations. Performing a urethral dilatation alone has a high risk of recurrence, with a 90% chance of scar tissue returning once it has developed. Optilume addresses this issue with a more effective, long-term solution.
“This condition is quite common in men, and treatment can often be challenging due to the associated pain and discomfort,” said Mr. Rai. “Optilume offers a lower failure rate, between 25-27%, meaning fewer patients will require reconstructive surgery or have to perform self-dilatation. Importantly, all treatment options are still presented to patients from the outset, giving them greater choice. It’s a significant advantage to have a minimally invasive, day-case procedure like Optilume available for patients.”
Optilume is a unique balloon dilation technology combined with a drug-coated delivery system that helps widen the urethra and prevent scar tissue recurrence. The success of the first procedure at MKUH marks an important milestone for the hospital and the wider healthcare community across Bedfordshire, Luton, and Milton Keynes. This milestone underscores the hospital’s dedication to innovation and excellence in patient care, ensuring that local patients have access to the latest medical technologies.
Comments